Thinly traded micro cap BioXcel Therapeutics (NASDAQ:BTAI) perks up 4% premarket on light volume on the heels of the FDA’s sign-off
on a Phase 1b/2 clinical trial, RELEASE, evaluating BXCL501, a
sublingual thin film formulation of the sedative dexmedetomidine, for
the treatment of opioid withdrawal symptoms.
The candidate is also being developed to treat
agitation in schizophrenia and bipolar disorder patients and agitation
related to dementia.
https://seekingalpha.com/news/3538492-fda-signs-off-on-bioxcel-ind-for-study-of-bxcl501-for-opioid-withdrawal
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.